

Haeseong Park

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4038411/publications.pdf>

Version: 2024-02-01

81
papers

3,543
citations

279798

23
h-index

149698

56
g-index

82
all docs

82
docs citations

82
times ranked

4603
citing authors

#	ARTICLE	IF	CITATIONS
1	Selection of Neoadjuvant Treatment Arms in Trials of Patients With Squamous Cell Cancer of the Esophagus. <i>JAMA Surgery</i> , 2022, 157, 83.	4.3	0
2	SURPASS-2 trial design: A phase 2, open-label study of ADP-A2M4CD8 SPEAR T cells in advanced esophageal or esophagogastric junction cancers.. <i>Journal of Clinical Oncology</i> , 2022, 40, TPS363-TPS363.	1.6	2
3	Ramucirumab and irinotecan in patients with previously treated gastroesophageal adenocarcinoma: Final analysis of a phase II trial.. <i>Journal of Clinical Oncology</i> , 2022, 40, 284-284.	1.6	0
4	A phase I clinical trial to evaluate the safety, tolerability, and pharmacokinetics of TST001 in patients with locally advanced or metastatic solid tumors.. <i>Journal of Clinical Oncology</i> , 2022, 40, TPS375-TPS375.	1.6	4
5	A pilot study of liposomal irinotecan plus 5-FU/ LV combined with paricalcitol in patients with advanced pancreatic cancer which progressed on gemcitabine-based therapy.. <i>Journal of Clinical Oncology</i> , 2022, 40, 566-566.	1.6	2
6	Durvalumab plus tremelimumab alone or in combination with low-dose or hypofractionated radiotherapy in metastatic non-small-cell lung cancer refractory to previous PD(L)-1 therapy: an open-label, multicentre, randomised, phase 2 trial. <i>Lancet Oncology</i> , The, 2022, 23, 279-291.	10.7	118
7	Phase 1b/2, open-label, dose-escalation and expansion trial of tucatinib in combination with trastuzumab with and without oxaliplatin-based chemotherapy or pembrolizumab in patients with unresectable or metastatic HER2+ gastrointestinal cancers (trial in progress).. <i>Journal of Clinical Oncology</i> , 2022, 40, TPS376-TPS376.	1.6	4
8	Abstract OT1-02-02: A global, phase 2 study of ARX788 in patients with HER2-positive metastatic breast cancer whose disease is resistant or refractory to T-DM1, and/or T-DXd, and/or tucatinib-containing regimens. <i>Cancer Research</i> , 2022, 82, OT1-02-02-OT1-02-02.	0.9	0
9	Abstract GS4-10: Neratinib + fulvestrant + trastuzumab for hormone receptor-positive, <i>HER2</i>-mutant metastatic breast cancer and neratinib + trastuzumab for triple-negative disease: Latest updates from the SUMMIT trial. <i>Cancer Research</i> , 2022, 82, GS4-10-GS4-10.	0.9	6
10	First-in-Human Phase I/II ICONIC Trial of the ICOS Agonist Vopratelimab Alone and with Nivolumab: ICOS-High CD4 T-Cell Populations and Predictors of Response. <i>Clinical Cancer Research</i> , 2022, 28, 3695-3708.	7.0	26
11	Targeting HER2-positive metastatic breast cancer with ARX788, a novel anti-HER2 antibody-drug conjugate in patients whose disease is resistant or refractory to T-DM1, and/or T-DXd, and/or tucatinib-containing regimens.. <i>Journal of Clinical Oncology</i> , 2022, 40, TPS1112-TPS1112.	1.6	0
12	First-in-human study of the B7-H4 antibody-drug conjugate (ADC) AZD8205 in patients with advanced/metastatic solid tumors.. <i>Journal of Clinical Oncology</i> , 2022, 40, TPS3153-TPS3153.	1.6	2
13	Neratinib plus fulvestrant plus trastuzumab (N+F+T) for hormone receptor-positive (HR+), HER2-negative, <i>HER2</i>-mutant metastatic breast cancer (MBC): Outcomes and biomarker analysis from the SUMMIT trial.. <i>Journal of Clinical Oncology</i> , 2022, 40, 1028-1028.	1.6	9
14	Impact of body mass index on treatment and outcomes in patients with early hormone receptor-positive breast cancer receiving endocrine therapy with or without palbociclib in the PALLAS trial.. <i>Journal of Clinical Oncology</i> , 2022, 40, 518-518.	1.6	4
15	Phase I trial of CA-4948, an IRAK4 inhibitor, in combination with FOLFOX/PD-1 inhibitor +/- trastuzumab for untreated unresectable gastric and esophageal cancer.. <i>Journal of Clinical Oncology</i> , 2022, 40, TPS4168-TPS4168.	1.6	0
16	First-in-human phase 1 trial of ELI-002 immunotherapy as treatment for subjects with Kirsten rat sarcoma (KRAS)-mutated pancreatic ductal adenocarcinoma and other solid tumors.. <i>Journal of Clinical Oncology</i> , 2022, 40, TPS2701-TPS2701.	1.6	10
17	Phase Ia dose-escalation study of the anti-BTLA antibody icatolimab as a monotherapy in patients with advanced solid tumor.. <i>Journal of Clinical Oncology</i> , 2022, 40, 2643-2643.	1.6	9
18	A phase I trial of temsirolimus and erlotinib in patients with refractory solid tumors. <i>Cancer Chemotherapy and Pharmacology</i> , 2021, 87, 337-347.	2.3	5

#	ARTICLE	IF	CITATIONS
19	Immunity, immunotherapy, and rectal cancer: A clinical and translational science review. <i>Translational Research</i> , 2021, 231, 124-138.	5.0	11
20	Targeting <i>HER2</i> (<i>ERBB2</i>) mutation-positive advanced biliary tract cancers with neratinib: Results from the phase II SUMMIT “basket” trial. <i>Journal of Clinical Oncology</i> , 2021, 39, 320-320.	1.6	24
21	KRYSTAL-2: A phase I/II trial of adagrasib (MRTX849) in combination with TNO155 in patients with advanced solid tumors with KRAS G12C mutation. <i>Journal of Clinical Oncology</i> , 2021, 39, TPS146-TPS146.	1.6	27
22	ctDNA MRD Detection and Personalized Oncogenomic Analysis in Oligometastatic Colorectal Cancer From Plasma and Urine. <i>JCO Precision Oncology</i> , 2021, 5, 378-388.	3.0	26
23	COVID-19 vaccine guidance for patients with cancer participating in oncology clinical trials. <i>Nature Reviews Clinical Oncology</i> , 2021, 18, 313-319.	27.6	103
24	Phase I study of BJ-001, a tumor-targeting interleukin-15 fusion protein, in patients with solid tumor. <i>Journal of Clinical Oncology</i> , 2021, 39, e14545-e14545.	1.6	3
25	Phase 1/2 study of eprenetapopt (APR-246) in combination with pembrolizumab in patients with solid tumor malignancies. <i>Journal of Clinical Oncology</i> , 2021, 39, TPS3161-TPS3161.	1.6	2
26	A phase II study of short course FOLFOX chemotherapy with either nivolumab (Nivo) or Nivo plus radiation in the first line treatment of metastatic or unresectable gastroesophageal (GEA) cancers. <i>Journal of Clinical Oncology</i> , 2021, 39, TPS4157-TPS4157.	1.6	0
27	Capitalizing on Success of Systemic Therapy to Improve Outcomes of Intermediate-Stage HCC. <i>JCO Oncology Practice</i> , 2021, , OP.21.00451.	2.9	0
28	A phase II study of everolimus in patients with advanced solid malignancies with TSC1, TSC2, NF1, NF2 or STK11 mutations. <i>Journal of Thoracic Disease</i> , 2021, 13, 4054-4062.	1.4	9
29	Race and ethnicity representation in clinical trials: findings from a literature review of Phase I oncology trials. <i>Future Oncology</i> , 2021, 17, 3271-3280.	2.4	24
30	A single-institution phase I feasibility study of dose-escalated IMRT for non-operative locally advanced esophageal carcinoma. <i>Clinical and Translational Radiation Oncology</i> , 2021, 30, 19-25.	1.7	1
31	Nonoperative Rectal Cancer Management With Short-Course Radiation Followed by Chemotherapy: A Nonrandomized Control Trial. <i>Clinical Colorectal Cancer</i> , 2021, 20, e185-e193.	2.3	20
32	Safety and Efficacy of Vorinostat Plus Sirolimus or Everolimus in Patients with Relapsed Refractory Hodgkin Lymphoma. <i>Clinical Cancer Research</i> , 2020, 26, 5579-5587.	7.0	16
33	Reply to T.J.A. Dekker. <i>Journal of Clinical Oncology</i> , 2020, 38, 3351-3352.	1.6	0
34	FOLFIRINOX for the Treatment of Advanced Gastroesophageal Cancers. <i>JAMA Oncology</i> , 2020, 6, 1231.	7.1	12
35	Gastric Cancer with Radiographically Occult Metastatic Disease: Biology, Challenges, and Diagnostic Approaches. <i>Cancers</i> , 2020, 12, 592.	3.7	3
36	Interferon-Induced IDO1 Mediates Radiation Resistance and Is a Therapeutic Target in Colorectal Cancer. <i>Cancer Immunology Research</i> , 2020, 8, 451-464.	3.4	63

#	ARTICLE	IF	CITATIONS
37	Margetuximab plus pembrolizumab in patients with previously treated, HER2-positive gastro-oesophageal adenocarcinoma (CP-MGAH22â€“05): a single-arm, phase 1bâ€“2 trial. <i>Lancet Oncology, The</i> , 2020, 21, 1066-1076.	10.7	130
38	Tolerability and safety of EUS-injected adenovirus-mediated double-suicide gene therapy with chemotherapy in locally advanced pancreatic cancer: a phase 1 trial. <i>Gastrointestinal Endoscopy</i> , 2020, 92, 1044-1052.e1.	1.0	43
39	Antitumor Activity and Safety of Trastuzumab Deruxtecan in Patients With HER2-Lowâ€“Expressing Advanced Breast Cancer: Results From a Phase Ib Study. <i>Journal of Clinical Oncology</i> , 2020, 38, 1887-1896.	1.6	465
40	Targeting HER2 with Trastuzumab Deruxtecan: A Dose-Expansion, Phase I Study in Multiple Advanced Solid Tumors. <i>Cancer Discovery</i> , 2020, 10, 688-701.	9.4	212
41	Trial in progress: A phase II open-label, randomized study of PARP inhibition (olaparib) either alone or in combination with anti-PD-L1 therapy (atezolizumab) in homologous DNA repair (HDR) deficient, locally advanced or metastatic non-HER2-positive breast cancer.. <i>Journal of Clinical Oncology</i> , 2020, 38, TPS1102-TPS1102.	1.6	7
42	Initial safety run-in findings with bavituximab plus pembrolizumab in patients with advanced gastric or gastroesophageal cancer.. <i>Journal of Clinical Oncology</i> , 2020, 38, e16537-e16537.	1.6	1
43	A phase I, open-label, multicenter, first-in-human study of the safety, tolerability, pharmacokinetics, and antitumor activity of TPX-0022, a novel MET/CSF1R/SRC inhibitor, in patients with advanced solid tumors harboring genetic alterations in MET.. <i>Journal of Clinical Oncology</i> , 2020, 38, TPS3663-TPS3663.	1.6	2
44	Final results of a phase II trial of first-line FOLFIRINOX for advanced gastroesophageal cancers.. <i>Journal of Clinical Oncology</i> , 2020, 38, 4532-4532.	1.6	0
45	A pilot study of liposomal irinotecan plus 5-FU/LV combined with paricalcitol in patients with advanced pancreatic cancer progressed on gemcitabine-based therapy.. <i>Journal of Clinical Oncology</i> , 2020, 38, TPS793-TPS793.	1.6	0
46	Comprehensive Genomic Profiling of Hodgkin Lymphoma Reveals Recurrently Mutated Genes and Increased Mutation Burden. <i>Oncologist</i> , 2019, 24, 219-228.	3.7	30
47	Efficacy and Safety of Avelumab for Patients With Recurrent or Refractory Ovarian Cancer. <i>JAMA Oncology</i> , 2019, 5, 393.	7.1	303
48	Randomized controlled trial of high-dose versus standard-dose vitamin D3 for prevention of aromatase inhibitor-induced arthralgia. <i>Breast Cancer Research and Treatment</i> , 2019, 177, 427-435.	2.5	11
49	Trastuzumab deruxtecan (DS-8201a) in patients with advanced HER2-positive gastric cancer: a dose-expansion, phase 1 study. <i>Lancet Oncology, The</i> , 2019, 20, 827-836.	10.7	154
50	Trastuzumab deruxtecan (DS-8201a) in patients with advanced HER2-positive breast cancer previously treated with trastuzumab emtansine: a dose-expansion, phase 1 study. <i>Lancet Oncology, The</i> , 2019, 20, 816-826.	10.7	252
51	First-in-human study of REGN3767 (R3767), a human LAG-3 monoclonal antibody (mAb), Â± cemiplimab in patients (pts) with advanced malignancies.. <i>Journal of Clinical Oncology</i> , 2019, 37, 2508-2508.	1.6	26
52	Phase I study of the Aurora A kinase (AurA) inhibitor TAS-119 with paclitaxel (P) in advanced solid tumors.. <i>Journal of Clinical Oncology</i> , 2019, 37, 3031-3031.	1.6	2
53	Pembrolizumab in previously treated metastatic esophageal cancer: Longer term follow-up from the phase 2 KEYNOTE-180 Study.. <i>Journal of Clinical Oncology</i> , 2019, 37, 4032-4032.	1.6	4
54	A randomized phase II study of nab-paclitaxel + durvalumab + neoantigen vaccine versus nab-paclitaxel + durvalumab in metastatic triple-negative breast cancer (mTNBC).. <i>Journal of Clinical Oncology</i> , 2019, 37, TPS1114-TPS1114.	1.6	6

#	ARTICLE	IF	CITATIONS
55	Esophageal and Esophagogastric Junction Cancers, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology. Journal of the National Comprehensive Cancer Network: JNCCN, 2019, 17, 855-883.	4.9	672
56	A phase Ib trial of anti-VEGFR/PDGFR vorolanib combined with immune checkpoint inhibitors (CPIs) in solid tumors.. Journal of Clinical Oncology, 2019, 37, TPS472-TPS472.	1.6	0
57	A study of REGN3767, an anti-LAG-3 antibody, alone and in combination with cemiplimab (REGN2810), an anti-PD1 antibody in advanced cancers.. Journal of Clinical Oncology, 2019, 37, TPS41-TPS41.	1.6	0
58	Ramucirumab and irinotecan in patients with previously treated gastroesophageal adenocarcinoma.. Journal of Clinical Oncology, 2019, 37, TPS4150-TPS4150.	1.6	1
59	Abstract CT212: Combining pembrolizumab with locally delivered radiation therapy for the treatment of metastatic esophageal cancer. , 2019, , .		1
60	Abstract 4182: Community and cancer registry collaboration to reduce persistent stomach cancer disparity in Korean Americans: Asian American Stomach Cancer Task Force. , 2019, , .		0
61	Trastuzumab deruxtecan (DS-8201a) in subjects with HER2-expressing solid tumors: Long-term results of a large phase 1 study with multiple expansion cohorts.. Journal of Clinical Oncology, 2018, 36, 2501-2501.	1.6	68
62	Margetuximab (M) plus pembrolizumab (P) in ERBB2-amplified PD-L1+ gastroesophageal adenocarcinoma (GEA) post trastuzumab (T).. Journal of Clinical Oncology, 2018, 36, 4030-4030.	1.6	9
63	A study of REGN3767, an anti-LAG-3 antibody, alone and in combination with cemiplimab (REGN2810), an anti-PD1 antibody, in advanced cancers.. Journal of Clinical Oncology, 2018, 36, TPS3127-TPS3127.	1.6	4
64	Updated results of phase 1 study of DS-8201a in subjects with HER2-expressing gastric cancer.. Journal of Clinical Oncology, 2018, 36, 118-118.	1.6	5
65	A phase II trial of first-line FOLFIRINOX for patients with advanced gastroesophageal adenocarcinoma.. Journal of Clinical Oncology, 2018, 36, 89-89.	1.6	2
66	Results from a phase I study of anecaliximab in combination with FOLFIRI and bevacizumab in patients with second line metastatic colorectal cancer.. Journal of Clinical Oncology, 2018, 36, 3578-3578.	1.6	0
67	Progress in PD-1-based Immunotherapy: New Mechanistic Insight May Provide Expanded Hope for Application to Colon and Gastrointestinal Cancers. Gastroenterology, 2017, 153, 1162-1163.	1.3	3
68	Pacritinib to inhibit JAK/STAT signaling in refractory metastatic colon and rectal cancer. Journal of Gastrointestinal Oncology, 2017, 8, 985-989.	1.4	14
69	Single agent activity of DS-8201a, a HER2-targeting antibody-drug conjugate, in heavily pretreated HER2 expressing solid tumors.. Journal of Clinical Oncology, 2017, 35, 108-108.	1.6	23
70	Phase I dose-escalation study of the mTOR inhibitor sirolimus and the HDAC inhibitor vorinostat in patients with advanced malignancy. Oncotarget, 2016, 7, 67521-67531.	1.8	44
71	North Central Cancer Treatment Group N10C2 (Alliance). Menopause, 2015, 22, 627-632.	2.0	18
72	Synergism between bosutinib (SKI-606) and the Chk1 inhibitor (PF-00477736) in highly imatinib-resistant BCR/ABL+ leukemia cells. Leukemia Research, 2015, 39, 65-71.	0.8	18

#	ARTICLE	IF	CITATIONS
73	Phase I study of the mTOR inhibitor sirolimus and the HDAC inhibitor vorinostat in patients with advanced malignancies.. Journal of Clinical Oncology, 2015, 33, 2584-2584.	1.6	0
74	Disseminated histoplasmosis in peripheral blood smear. Blood, 2014, 123, 1445-1445.	1.4	5
75	NCCTG N10C2 (Alliance): A double-blind, placebo-controlled study of magnesium supplements to reduce menopausal hot flashes.. Journal of Clinical Oncology, 2014, 32, 9508-9508.	1.6	0
76	Abstract CT405: A phase 1 study of neoadjuvant chemotherapy with gemcitabine plus nab-paclitaxel, followed by concurrent chemoradiation with gemcitabine, sorafenib, and vorinostat in locally advanced pancreatic cancer. , 2014, , .		0
77	Acute Changes in N-Terminal Pro-B-Type Natriuretic Peptide During Hospitalization and Risk of Readmission and Mortality in Patients With Heart Failure. American Journal of Cardiology, 2011, 107, 1191-1195.	1.6	61
78	A pilot phase II trial of magnesium supplements to reduce menopausal hot flashes in breast cancer patients. Supportive Care in Cancer, 2011, 19, 859-863.	2.2	27
79	A Systematic Review of Barriers and Interventions to Improve Appropriate Use of Therapies for Sickle Cell Disease. Journal of the National Medical Association, 2009, 101, 1022-1033.	0.8	135
80	Usefulness of Cystatin C and Prognosis Following Admission for Acute Heart Failure. American Journal of Cardiology, 2009, 104, 389-392.	1.6	46
81	Hydroxyurea for Sickle Cell Disease: A Systematic Review for Efficacy and Toxicity in Children. Pediatrics, 2008, 122, 1332-1342.	2.1	189